semaglutide discontinuation US, Japan Patients With Diabetes Discontinue After First Year Majority of adults with obesity

While it is believed that semaglutide leads to gastrointestinal disorders less than 5% of the time, transient, mild-to-moderate bouts of the following issues are commonplace among GLP-1 drugs: Nausea : 44% Vomiting: 25% Diarrhea: 32% Constipation: 23% Abdominal pain: 10% Fatigue, Dizziness, Headache Clinical data does not support the idea that semaglutide directly causes dizziness, headaches, or significant fatigue

593 Wu et al

Janice Simmonds-Fisher, MBBS, DNM BIOregeneration Integrated Medical Centre If you've been struggling to lose weight, trying every diet and exercise programme without success, you are not alone

Johnstad PG

Noom this year partnered with healthcare company Accolade to provide evidence-based obesity care

In a 68-week clinical trial, participants receiving semaglutide experienced an average body-weight reduction of 14.9% from baseline